Title: Composition for Suppressing Expression of Target Gene
Filed: Oct. 24, 2005 PCT Filed: Oct. 24, 2005
Lead Inventor: Masahiro Yamauchi, Kyowa Hakko Kogyo
According to the patent application's abstract, the invention comprises a "composition for suppressing the expression of a target gene and the like." Specifically, the invention is "a composition, comprising an RNA-encapsulated liposome [made of] complex particles comprising … a lead particle and an RNA comprising a sequence consisting of 15 to 30 contiguous nucleotides of a target gene mRNA and a sequence complementary to the sequence, and a lipid membrane for coating the complex particles."
The components of the lipid membrane "can be solved in a polar organic solvent, and wherein the polar organic solvent can be contained in a liquid at such a concentration that the constituent components of the lipid membrane are dispersible and the complex particles are dispersible," the abstract adds.
Title: Short Interfering RNA and microRNA Compounds, and Methods of Designing, Making, and Using the Same
Filed: Oct. 22, 2004 PCT Filed: Oct. 22, 2004
Lead Inventor: Zissimos Mourelatos, University of Pennsylvania
The invention, the patent application's abstract states, comprises "methods of identifying, designing, and synthesizing uniquely targeting siRNA nucleotide sequences for a target mRNA sequence of a target species … [as well as] methods of identifying, designing, and synthesizing miRNA nucleotide sequences that does not function as a siRNA nucleotide sequence for mRNA of a target species."
The patent application also claims a "method of inhibiting expression of a target mRNA molecule … siRNA molecules … [and] miRNA molecules that do not function as siRNA nucleotide sequences for mRNA of a target species," according to the abstract.
Title: Delivery of siRNA by Neutral Lipid Compositions
Filed: April 17, 2006 PCT Filed: April 17, 2006
Lead Inventor: Anil Sood, MD Anderson Cancer Center
The invention "relates to the fields of molecular biology and drug delivery," the patent application's abstract states. "In certain embodiments, the … invention provides methods for the delivery of a [short interfering nucleic acid] to a cell via a neutral liposome. These methods may be used to treat a disease, such as cancer."
Title: Hybrid Interfering RNA
Filed: May 24, 2006 PCT Filed: May 24, 2006
Lead Inventor: Josephine Anne Milner, University of York
"The invention relates to a hybrid interfering RNA molecule comprising a duplex RNA and a single-stranded DNA molecule and its use in the ablation of mRNA and in polymerase chain reactions," the patent application's abstract states.
Title: RNAi-Mediated Inhibition of HTRA1 for Treatment of Macular Degeneration
Filed: July 1, 2008
Lead Inventor: Jon Chatterton, Alcon
"RNA interference is provided for inhibition of HTRA1 mRNA expression for treating patients with an HTRA1-mediated ocular disorder," the patent application's abstract states. "In particular, methods are provided for treating age-related macular degeneration and using interfering RNA molecules that attenuate expression of HTRA1 in patients having AMD or at risk of developing AMD."
Title: System and Method for Identification of microRNA Target Sites and Corresponding Targeting microRNA Sequences
Filed: June 9, 2008
Lead Inventor: Tien Huynh, IBM
The invention, the patent application's abstract states, comprises "a method for determining whether a nucleotide sequence contains a microRNA binding site and which microRNA will bind thereto.
"For example, in one aspect of the invention, a method for determining whether a nucleotide sequence contains a microRNA binding site and which microRNA sequence will bind thereto is comprised of the following steps: one or more patterns are generated by processing a collection of known mature microRNA sequences; the reverse complement of each generated patter is then computed; one or more attributes are then assigned to the reverse complement of the one or more generated patterns," the abstract states.
Next in the process, "the one or more patterns that correspond to a reverse complement having one or more assigned attributes that satisfy at least one criterion are thereafter sub-selected," the abstract adds. "Each sub-selected pattern is then used to analyze the nucleotide sequence, such that a determination is made whether the nucleotide sequence contains a microRNA binding site and which microRNA sequence will bind thereto."